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with asymptomatic CS on optimized medical ther‑
apy (OMT). As the risk is cumulative, the annual 
risk level of about 2.5% to 3.0% indicates—for in‑
stance for a 50 ‑year ‑old man with an asymptomat‑
ic CS on contemporary OMT—a statistical stroke 
risk of about 25% to 30% by the age of 60 and 
50% to 60% by the age of 70 (the actual risk can 
be still higher when additional risk factors, such 
as diabetes, are present).2 As 85% of strokes occur 
without a warning sign, and of those who survive 
stroke (about 40% at 5 years) about half are dis‑
abled,2 many families and physicians find it diffi‑
cult to ignore such a risk.4 This is particularly rel‑
evant because contemporary CS revascularization 
studies continue to enroll patients with CS strokes 
despite OMT;  this provdes circumstantial evidence 
that OMT, at least in some patients, does not suf‑
ficiently protect against stroke.4
So why is the management of asymptomatic 
CS (to some at least) controversial today? Prin‑
cipal reasons seem to stem from: 1) definition 
problems (“asymptomatic” vs “symptomatic” CS; 
“stroke” vs “cerebral infarct”); 2) fundamental dif‑
ferences between the low ‑risk general population 
and higher ‑risk populations with atherosclerotic 
disease manifestations; 3) poor appreciation of 
increased stroke risk characteristics in CS; 4) risk 
of intervention (until recently) of about 3%9; and 
5) lack of randomized data (OMT vs OMT + inter‑
vention) in current populations with asymptom‑
atic CS across the whole risk spectrum.
What is the meaning of “symptomatic” in re‑
lation to CS? The English language, in contrast to 
many others, differentiates between “symptoms” 
and “signs.” A symptom is an indication of disease 
perceived by the patient and reported by the pa‑
tient. Symptoms of CS ‑associated cerebral ischemia 
include ipsilateral TIA or clinical stroke.2,10 A sign is 
Atherosclerotic stenosis of the internal carot‑
id artery of 50% or more is a relatively common 
pathology (about 2% to 8% of the general popu‑
lation aged 60 to 80 years), with the prevalence 
similar to that of nonvalvular atrial fibrillation.1 
However, patients with manifest atherosclero‑
sis in other vascular beds show a significantly 
greater prevalence of carotid stenosis (CS) and 
a greater risk of cerebral symptoms that occur 
through the thromboembolic or hemodynam‑
ic mechanisms.2
The ACST ‑1 trial3 in 3120 patients with asymp‑
tomatic CS followed for 10 years demonstrated, 
with an elective (rather than deferred) CS revas‑
cularization, a profound absolute risk reduction in 
nonperioperative stroke by 5.9% at 5 years (risk re‑
duction from 11.0% to 5.1%) and 6.1% at 10 years 
(risk reduction from 16.9% to 10.8%, with the mag‑
nitude of the effect maintained in patients on lipid‑
‑lowering therapy).3 Surprisingly, in the absence of 
any new randomized data, there have been vocal 
calls recently to disregard the level ‑1 evidence from 
the ACST ‑1 trial through either ignoring the trial 
completely in some meta ‑analyses4 or attempt‑
ing to construct an alternative body of “new evi‑
dence.” Such “new ‑evidence” observational stud‑
ies, performed not infrequently in as few as 100 
subjects5 (rather than the usually referenced 1153 
subjects)5 followed for a relatively short time5 (and 
with most transient ischemic attacks [TIAs] lead‑
ing—rightly—to carotid revascularization to pre‑
vent strokes)5 have been used to claim that “med‑
ical intervention alone is best for prevention of 
strokes”4 or that “the benefits of carotid revascu‑
larization remain uncertain”6 and “revasculariza‑
tion is not the solution”.6 In contrast, 2 recent in‑
dependent studies demonstrated an annual stroke 
rate of 2.4%7 or 2.9%8 in vascular clinic patients 
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cerebral blood flow normalization). While more 
evidence (including external validation and es‑
tablishing reference ranges) is needed before ret‑
inal function tests can be adopted into the stan‑
dard risk evaluation portfolio in “asymptomatic” 
CS, the work by Machalińska et al16 is an impor‑
tant novel signal.
Concluding remarks and further discussion of 
the OMT vs OMT + intervention management 
strategy, the ongoing CREST ‑2 trial (Carotid Re‑
vascularization Endarterectomy Versus Stenting 
Trial 2), and progress in device technology can be 
found in the Conclusion section of Supplementa‑
ry material.
Supplementary material Supplementary materi‑
al is available with the article at www.pamw.pl.
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an observable physical phenomenon indicative of 
the presence of a pathology or disease. Signs are de‑
tected by the physician through clinical examination 
and accessory investigations. A clinically ‑silent cere‑
bral infarct ipsilateral to CS is a sign, not a symptom, 
and the patient is, strictly speaking, “asymptomat‑
ic.” In such patients, however, there is evidence for 
an increased risk of further, clinically symptomat‑
ic, brain injury likely to occur in the absence of an 
intervention.2,8 While the definition of stroke in‑
cludes an episode of clinically manifest neurologi‑
cal dysfunction,10 according to the same guidelines, 
the term “stroke” may be also used for brain infarc‑
tion in the absence of clinical symptoms.10 Accord‑
ing to some authors, patients with TIA or stroke be‑
come automatically “asymptomatic” from the point 
of 6 months after the event onwards.3,9,11 Further 
confusions arise from the fact that different studies 
have used different time points to change the “symp‑
tomatic” / “asymptomatic” label, such as 1, 3, 4, or 
12 months.12 More accurate terms have been pro‑
posed, such as “recently symptomatic” and “remote‑
ly symptomatic.”12 The above, and other, inconsis‑
tencies greatly confuse physicians, leading to differ‑
ent approaches to the same patient type by various 
specialties or in various medical centers or countries.
A key question is whether it is ethical today to 
wait for clinically manifest symptoms as a thresh‑
old for intervention in patients with CS with signs 
of cerebral ischemia (or other increased ‑risk fea‑
tures), particularly in centers (and with novel tech‑
nologies) that may offer a low ‑risk intervention. 
A selective approach to evidence (including ignor‑
ing level ‑1 data)4 and basing recommendations 
largely on observational studies,4,6 confusion be‑
tween symptoms and signs of cerebral ischemia, 
and controversies over the CS features associated 
with an increased risk of stroke have led to large 
differences in recommendations issued by different 
specialties and professional societies.13,14 However, 
the recent joint guidelines15 of the European Soci‑
ety of Cardiology  and European Society of Vascu‑
lar Surgery, endorsed by the European Stroke Or‑
ganization, provide an important attempt to re‑
solve at least some of the key decision ‑making is‑
sues in asymptomatic CS. The guidelines are dis‑
cussed in Supplementary material.
With their pioneering demonstration of the ef‑
fect of carotid revascularization on retinal func‑
tion in this issue of the Polish Archives of Inter-
nal Medicine (Pol Arch Intern Med), Machalińska 
et al16 expand our understanding of the CS im‑
pacts. The retina is well ‑known to be extremely 
sensitive to ischemia.17,18 Acute ocular syndromes, 
resulting from acute hemodynamic insufficiency 
of the ophthalmic/retinal artery, are a fundamen‑
tal part of the symptomatic presentation spectrum 
of CS.10,15,17,18 Employing a battery of retinal func‑
tion tests in an “asymptomatic” CS patient series, 
Machalińska et al16 found, with carotid revascular‑
ization, a significant improvement in neuroretinal 
function on a multimodality electroretinogram in 
the eye ipsilateral to the CS (also, to a lesser extent, 
in the contralateral eye which may benefit due to 
